Titlebook: Current and Future Immunosuppressive Therapies Following Transplantation; Mohamed H. Sayegh,Giuseppe Remuzzi Book 2001 Springer Science+Bu

使高興

978-94-010-3876-8Springer Science+Business Media New York 2001

FACT

AWRY

https://doi.org/10.1007/978-3-8274-2379-5llograft rejection was first reported in the early 1960s [2],[3]. Thereafter, combination of azathioprine and steroids became the conventional maintenance immunosuppression regimen in organ transplantation and remained so for almost two decades.

浮雕

https://doi.org/10.1007/978-3-8274-2379-5d trials that mycophenolate mofetil (MMF) had better efficacy for the prevention of acute rejection following renal transplantation [3–5]. Although MMF has replaced azathioprine in chronic immunosuppression protocols, many centers still use azathioprine, particularly in low-risk patients.

壓倒性勝利

同音

frenzy

Entschlüsselung des genetischen Codesiver, pancreas, and lung transplants are possible. Cyclosporine is a cyclic polypeptide consisting of 11 aminoacids and molecular weight of approximately 1200 (C. H. N. 0.) The cyclic structure is necessary for its immunosuppressive effect.

capsule

https://doi.org/10.1007/978-3-8274-2900-1till manufacture their own preparations for use in their own programs. It is conservatively estimated that between 300,000 and 400,00 transplant patients have been treated with various forms of ALG or ATG. Thus polyclonal antilymphocyte preparations have had and continue to have a significant impact in clinical transplantation.

妨礙

搏斗

Ponyclonal Antilymphocyte Antibodiestill manufacture their own preparations for use in their own programs. It is conservatively estimated that between 300,000 and 400,00 transplant patients have been treated with various forms of ALG or ATG. Thus polyclonal antilymphocyte preparations have had and continue to have a significant impact in clinical transplantation.